Motus GI (MOTS) 10-Q 13 Nov 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2023	Nov. 03, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-38389
Entity Registrant Name	Motus GI Holdings, Inc.
Entity Central Index Key	0001686850
Entity Tax Identification Number	81-4042793
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1301 East Broward Boulevard
Entity Address, Address Line Two	3rd Floor
Entity Address, City or Town	Ft. Lauderdale
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33301
City Area Code	(954)
Local Phone Number	541 8000
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	MOTS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		578,515

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 5,724	$ 14,042
Accounts receivable	102	59
Inventory, current	407	488
Prepaid expenses and other current assets	509	781
Total current assets	6,742	15,370
Fixed assets, net	1,101	1,325
Inventory, non-current	374	511
Right-of-use assets	261	428
Other non-current assets	13	13
Total assets	8,491	17,647
Current liabilities:
Accounts payable and accrued expenses	1,466	1,969
Operating lease liabilities - current	220	245
Other current liabilities	62	53
Current portion of long-term debt, net of unamortized debt discount of $132 and $182, respectively	2,781	2,532
Total current liabilities	4,529	4,799
Contingent royalty obligation		1,212
Operating lease liabilities - non-current	34	178
Convertible note, net of unamortized debt discount of $64 and $108, respectively	3,936	3,892
Long-term debt, net of unamortized debt discount of $44 and $135, respectively	2,470	4,589
Total liabilities	10,969	14,670
Commitments and contingent liabilities (Note 9)
Shareholders’ (deficiency) equity
Common stock $0.0001 par value; 115,000,000 shares authorized; 530,449 and 310,494 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively
Additional paid-in capital	148,935	144,328
Accumulated deficit	(151,413)	(141,351)
Total shareholders’ (deficiency) equity	(2,478)	2,977
Total liabilities and shareholders’ (deficiency) equity	$ 8,491	$ 17,647

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Debt instrument, unamortized discount	$ 132	$ 182
Convertible note, unamortized discount, non-current	64	108
Debt instrument, unamortized discount, non-current	$ 44	$ 135
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	115,000,000	115,000,000
Common stock, shares issued	530,449	310,494
Common stock, shares outstanding	530,449	310,494

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Revenue	$ 86	$ 278	$ 255	$ 483
Operating expenses:
Cost of revenue - sales	22	83	62	166
Cost of revenue - impairment of inventory	26		221	159
Research and development	693	1,573	2,906	4,261
Sales and marketing	188	1,349	1,367	3,554
General and administrative	1,551	1,978	5,134	6,167
Total costs and expenses	2,480	4,983	9,690	14,307
Loss from Operations	(2,394)	(4,705)	(9,435)	(13,824)
Gain (loss) on change in estimated fair value of contingent royalty obligation	(53)	34	103	(29)
Finance expense, net	(222)	(310)	(707)	(1,001)
Foreign currency gain (loss)	(10)	17	(23)	(61)
Net loss	$ (2,679)	$ (4,964)	$ (10,062)	$ (14,915)
Basic loss per common share	$ (4.28)	$ (26.99)	$ (20.80)	$ (80.97)
Diluted loss per common share	$ (4.28)	$ (26.99)	$ (20.80)	$ (80.97)
Weighted average number of common shares outstanding, basic	626,470	183,897	483,711	184,210
Weighted average number of common shares outstanding, diluted	626,470	183,897	483,711	184,210

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Shareholders' (Deficiency) Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2021		$ 132,411,000	$ (122,754,000)	$ 9,657,000
balance, shares at Dec. 31, 2021	160,915
Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs of $55		3,004,000		3,004,000
Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs, shares	19,917
Share-based compensation		521,000		521,000
Net loss			(4,811,000)	(4,811,000)
Issuance of common shares upon vesting of restricted stock units
Issuance of common shares upon vesting of restricted stock units, shares	914
Issuance of common stock for board of directors’ compensation		235,000		235,000
Issuance of common stock for board of directors' compensation, shares	1,630
Ending balance, value at Mar. 31, 2022		136,171,000	(127,565,000)	8,606,000
balance, shares at Mar. 31, 2022	183,376
Beginning balance, value at Dec. 31, 2021		132,411,000	(122,754,000)	9,657,000
balance, shares at Dec. 31, 2021	160,915
Net loss				(14,915,000)
Ending balance, value at Sep. 30, 2022		138,431,000	(137,669,000)	762,000
balance, shares at Sep. 30, 2022	201,544
Beginning balance, value at Mar. 31, 2022		136,171,000	(127,565,000)	8,606,000
balance, shares at Mar. 31, 2022	183,376
Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs of $55		45,000		45,000
Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs, shares	541
Share-based compensation		461,000		461,000
Net loss			(5,140,000)	(5,140,000)
Issuance of common shares upon vesting of restricted stock units
Issuance of common shares upon vesting of restricted stock units, shares	278
Ending balance, value at Jun. 30, 2022		136,677,000	(132,705,000)	3,972,000
balance, shares at Jun. 30, 2022	184,195
Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs of $55		1,324,000		1,324,000
Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs, shares	17,208
Share-based compensation		441,000		441,000
Net loss			(4,964,000)	(4,964,000)
Issuance of common shares upon vesting of restricted stock units
Issuance of common shares upon vesting of restricted stock units, shares	277
Fractional shares settled in cash pursuant to reverse stock split		(11)		(11)
Fractional shares settled in cash pursuant to reverse stock split, shares	(136)
Ending balance, value at Sep. 30, 2022		138,431,000	(137,669,000)	762,000
balance, shares at Sep. 30, 2022	201,544
Beginning balance, value at Dec. 31, 2022		144,328,000	(141,351,000)	2,977,000
balance, shares at Dec. 31, 2022	310,494
Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs of $55		102,000		102,000
Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs, shares	7,942
Share-based compensation		222,000		222,000
Net loss			(4,386,000)	(4,386,000)
Ending balance, value at Mar. 31, 2023		144,652,000	(145,737,000)	(1,085,000)
balance, shares at Mar. 31, 2023	318,436
Beginning balance, value at Dec. 31, 2022		144,328,000	(141,351,000)	2,977,000
balance, shares at Dec. 31, 2022	310,494
Net loss				(10,062,000)
Ending balance, value at Sep. 30, 2023		148,935,000	(151,413,000)	(2,478,000)
balance, shares at Sep. 30, 2023	530,449
Beginning balance, value at Mar. 31, 2023		144,652,000	(145,737,000)	(1,085,000)
balance, shares at Mar. 31, 2023	318,436
Share-based compensation		49,000		49,000
Net loss			(2,997,000)	(2,997,000)
Private placement offering, net of financing fees of $731		3,070,000		3,070,000
Private placement offering, shares	35,000
Issuance of common shares upon vesting of restricted stock units
Issuance of common shares upon vesting of restricted stock units, shares	104
Ending balance, value at Jun. 30, 2023		147,771,000	(148,734,000)	(963,000)
balance, shares at Jun. 30, 2023	353,540
Share-based compensation		93,000		93,000
Net loss			(2,679,000)	(2,679,000)
Issuance of common shares upon exercise of warrants
Issuance of common shares upon exercise of warrants, shares	79,867
Issuance of common shares upon extinguishment of contingent royalty obligation, net of issuance fees of $38		1,071		1,071
Issuance of common shares upon extinguishment of contingent royalty obligation, shares	97,042
Ending balance, value at Sep. 30, 2023		$ 148,935,000	$ (151,413,000)	$ (2,478,000)
balance, shares at Sep. 30, 2023	530,449

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Shareholders' (Deficiency) Equity (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Statement of Stockholders' Equity [Abstract]
Net of issuance costs	$ 38	$ 731	$ 19	$ 55	$ 6	$ 111

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (10,062)	$ (14,915)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	341	381
Amortization of debt issuance costs	184	195
(Gain) loss on change in estimated fair value of contingent royalty obligation	(103)	29
Share- based compensation	364	1,423
Issuance of common stock for board of directors’ compensation		177
Impairment of inventory	221	159
Impairment of fixed assets		46
Amortization on operating lease right-of-use asset	176	253
Loss on lease termination	11
Changes in operating assets and liabilities:
Accounts receivable	(43)	(52)
Inventory	(16)	(843)
Prepaid expenses and other current assets	266	(167)
Accounts payable and accrued expenses	(503)	79
Operating lease liabilities - current and non-current	(183)	(255)
Other current liabilities	9	61
Net cash used in operating activities	(9,338)	(13,429)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets	(104)	(215)
Net cash used in investing activities	(104)	(215)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common shares	121	4,544
Fractional shares paid in cash pursuant to reverse stock split		(11)
Repayment of term debt	(2,010)
Gross proceeds from private placement offering	3,537
Equity financing fees	(524)	(158)
Net cash provided by financing activities	1,124	4,375
NET DECREASE IN CASH AND CASH EQUIVALENTS	(8,318)	(9,269)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	14,042	22,563
CASH AND CASH EQUIVALENTS AT END OF PERIOD	5,724	13,294
CASH PAID FOR:
Interest	690	779
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Common stock issued for prepaid board of directors’ compensation		58
Reclassification of inventory to fixed assets	13	163
Reclassification of prepaid expenses to fixed assets		4
Purchase of fixed assets in accounts payable and accrued expenses		12
Financing costs included in accounts payable and accrued expenses	38	13
Extinguishment of contingent royalty obligation	1,109
Operating lease liabilities arising from obtaining right-of-use assets		3
Non-cash issuance costs from private placement	264
Right-of-use asset obtained in exchange for lease obligation	$ 69

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Note 1 – Description of Business Motus GI Holdings, Inc. (the “Company”) was incorporated in Delaware, U.S.A. in September 2016. The Company and its subsidiaries, Motus GI Technologies, Ltd. and Motus GI, LLC, are collectively referred to as “Motus GI” or the “Company”. The Company has developed the Pure-Vu System, a medical device that has been cleared by the U.S. Food and Drug Administration (the “FDA”) to help facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and to help facilitate upper gastrointestinal (“GI”) endoscopy procedures. The Pure-Vu System has received a CE Mark in the EU for use in colonoscopy. The Pure-Vu System integrates with standard and slim colonoscopes, as well as gastroscopes, to improve visualization during colonoscopy and upper GI procedures while preserving established procedural workflow and techniques. Through irrigation and evacuation of debris, the Pure-Vu System is designed to provide better-quality exams. The Company received 510(k) clearance in October 2023 from the FDA for the Pure-Vu EVS System for use in the Upper GI tract and Gen 4 Colon and will commence market introduction of this product in the coming months. Both devices leverage the same Workstation and feature key enhancements such as a larger and more powerful suction channel, more efficient irrigation jets, a smaller profile distal tip that offers enhanced flexibility during insertion, enhanced navigation and a much easier bed side set up. The Company does not expect to generate significant revenue from product sales until it further expands its commercialization efforts, which is subject to significant uncertainty.

Basis of Presentation and Going

Basis of Presentation and Going Concern Uncertainty	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Going Concern Uncertainty	Note 2 – Basis of Presentation and Going Concern Uncertainty The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the 2022 10-K filed with the SEC on March 31, 2023. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information, the instructions for Form 10-Q and the rules and regulations of the SEC. Accordingly, since they are interim statements, the accompanying condensed consolidated financial statements do not include all of the information and notes required by GAAP for annual financial statements, but reflect all adjustments consisting of normal, recurring adjustments, that are necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. Interim results are not necessarily indicative of the results that may be expected for any future periods. The December 31, 2022 condensed consolidated balance sheet information was derived from the audited financial statements as of that date. The Company has generated limited revenues to date from the sale of products. The Company has never been profitable and has incurred significant net losses each year since its inception, including a loss of $ 10.1 9.3 5.7 151.4 In January and April 2023, the Company committed to a restructuring initiative designed to position the Company to explore a range of strategic and financing alternatives focused on maximizing stockholder value and accelerating the commercialization of the Pure-Vu System. If a strategic transaction is not completed, or if additional financing is not available, the Company may not be able to service our outstanding indebtedness and our payables and may have to file for bankruptcy protection or pursue a dissolution of the Company and liquidation of all of the Company’s remaining assets. In such an event, the amount of cash available for distribution to the Company’s shareholders, if any, will depend heavily on the timing of such decision, as with the passage of time the amount of cash available for distribution will be reduced as the Company continues to fund its operations and service the Company’s outstanding indebtedness. The Company cannot provide assurance as to the amount of cash that will be available to distribute to shareholders, if any, after paying its debts and other obligations and setting aside funds for reserves, nor as to the timing of any such distribution, if any. Such conditions raise substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments that may result from this uncertainty. The Company has financed its operations primarily through sales of equity-related securities and debt. In March 2021, we entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Oppenheimer & Co. Inc. (“Oppenheimer”), under which we may offer and sell from time to time common shares having an aggregate offering price of up to $ 25.0 7,942 102 19 On May 17, 2023, the Company entered into a securities purchase agreement with an accredited investor pursuant to which it agreed to issue and sell in a private placement an aggregate of (i) 35,000 241,134 276,134 12.675 12.6735 3.0 0.5 0.2

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Significant Accounting Policies The significant accounting policies used in preparation of these condensed consolidated financial statements for the nine months ended September 30, 2023 are consistent with those discussed in Note 3 to the consolidated financial statements in the Company’s 2022 Annual Report on Form 10-K. There have been no material changes to the Company’s significant accounting policies during the nine months ended September 30, 2023. Reverse Stock Split On November 2, 2023, the Company effected a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share, at a ratio of 1-for-15 (the “2023 Reverse Stock Split”) No fractional shares were issued in connection with the 2023 Reverse Stock Split. Stockholders who would otherwise be entitled to a fractional share of common stock instead receive a proportional cash payment. All of the Company’s historical share and per share information related to issued and outstanding common stock and outstanding options and warrants exercisable for common stock in these condensed consolidated financial statements have been adjusted, on a retroactive basis, to reflect the 2023 Reverse Stock Split. Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and include the accounts of the Company and its wholly owned subsidiaries, Motus Ltd., an Israel corporation, which has operations in Tirat Carmel, Israel, and Motus Inc., a Delaware corporation, which has operations in the U.S. All inter-company accounts and transactions have been eliminated in consolidation. Use of estimates The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Basic and diluted net loss per share Basic net loss per share is calculated by dividing the net loss attributable to common shareholders by the weighted average number of common shares outstanding during the applicable period. Diluted net loss per share is calculated by dividing the net loss attributable to common shareholders by the weighted average number of common shares outstanding for the applicable period, including any potentially dilutive securities such as stock options, unvested restricted stock, warrants, and other convertible instruments unless the result of inclusion would be antidilutive. The dilutive effect of restricted stock units subject to vesting and other share-based payment awards is calculated using the “treasury stock method,” which assumes that the “proceeds” from the exercise of these instruments are used to purchase common shares at the average market price for the period. The dilutive effect of convertible securities is calculated using the “if-converted method.” Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted calculation for the entire period being presented. Given the nominal exercise price of the Company’s issuance of Pre-Funded Warrants, such Pre-Funded Warrants are included in in the calculation of basic and diluted net loss per share as the exercise price per warrant is deemed nonsubstantive when compared to the fair value of the underlying common shares. The 161,266 The Company’s Convertible Note, on an as converted basis into common stock of 9,523 Schedule of Anti-dilutive Effect 2023 2022 2023 2022 Three Months Ended Nine Months Ended 2023 2022 2023 2022 Outstanding options 62,589 26,642 62,589 26,642 Unvested restricted stock units 1,079 1,630 1,079 1,630 Warrants 312,143 26,238 312,143 26,238 Total 375,811 54,510 375,811 54,510 Income taxes The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of September 30, 2023 and December 31, 2022, the Company had a full valuation allowance against its deferred tax assets. For the three and nine months ended September 30, 2023 and 2022, the Company recorded zero income tax expense. No tax benefit has been recorded in relation to the pre-tax loss for the three and nine months ended September 30, 2023 and 2022, due to a full valuation allowance to offset any deferred tax asset related to net operating loss carry forwards attributable to the losses. Accounting Pronouncements- Adopted In September 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses” to improve information on credit losses for financial assets and net investment in leases that are not accounted for at fair value through net income. ASU 2016-13 replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses. In April 2019 and May 2019, the FASB issued ASU No. 2019-04, “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments” and ASU No. 2019-05, “Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief” which provided additional implementation guidance on the previously issued ASU. In November 2019, the FASB issued ASU 2019-10, “Financial Instruments - Credit Loss (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842),” which defers the effective date for public filers that are considered smaller reporting companies as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company adopted this ASU on January 1, 2023. The adoption of this ASU did not result in a material impact to the consolidated financial statements and disclosures. Accounting Pronouncements- Not Yet Adopted In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 4 – Fair Value Measurements Liabilities measured and recorded at fair value on a recurring basis consisted of the following at September 30, 2023 and December 31, 2022: Schedule of Fair Value of Financial Assets and Liabilities September 30, 2023 Level 1 Level 2 Level 3 Fair Value Liabilities Contingent royalty obligation $ - $ - $ - $ - December 31, 2022 Level 1 Level 2 Level 3 Fair Value Liabilities Contingent royalty obligation $ - $ - $ 1,212 $ 1,212 Financial instruments with carrying values approximating fair value include cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses, and certain other current liabilities, due to their short-term nature. Debt instruments are measured at amortized cost on the Company’s consolidated balance sheets. If measured at fair value in the financial statements, these instruments would be classified as Level 2 in the fair value hierarchy. In estimating the fair value of the Company’s contingent royalty obligation, the Company used the discounted cash flow method as of September 12, 2023 and December 31, 2022. Based on the fair value hierarchy, the Company classified contingent royalty obligation within Level 3 because valuation inputs are based on projected revenues discounted to a present value. The contingent royalty obligation is re-measured at each balance sheet date and at September 12, 2023 using several assumptions, including the following: 1) estimated sales growth, 2) length of product cycle, 3) patent life, 4) discount rate ( 28.5 23 3 As noted in Note 9, under the Amendment Agreement, the Company extinguished its royalty obligation in exchange for equity interests. The Company measured the difference between the fair value of the shares of common stock issued and the carrying value (at a final fair value) of the royalty obligation as a gain. As the holder of a majority of the Royalty Payment Rights Certificates is considered a related party, as noted in Note 10, the Company recorded the retirement of the royalty obligation based on the total value of shares issued as well as the gain on settlement within equity as additional paid in capital as a capital transaction.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Inventory	Note 5 – Inventory Inventory is stated at lower of cost or net realizable value using the weighted average cost method and is evaluated at least annually for impairment. Write-downs for potentially obsolete or excess inventory are made based on management’s analysis of inventory levels, historical obsolescence and future sales forecasts. For the three and nine months ended September 30, 2023, an inventory impairment of $ 26 221 0 159 Inventory at September 30, 2023 and December 31, 2022 consisted of the following: Schedule of Inventory September 30, 2023 December 31, 2022 Raw materials $ 554 $ 697 Work-in-process 177 155 Finished goods 672 548 Inventory reserve (622 ) (401 ) Inventory, net $ 781 $ 999 Inventory, current $ 407 $ 488 Inventory, non-current $ 374 $ 511

Fixed assets, net

Fixed assets, net	9 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Fixed assets, net	Note 6 – Fixed assets, net Fixed assets, summarized by major category, consist of the following for the years ended: Schedule of Fixed Assets Net September 30, 2023 December 31, 2022 Office equipment $ 171 $ 171 Computers and software 321 321 Machinery 1,154 1,049 Lab and medical equipment 1,489 1,477 Leasehold improvements 200 200 Total 3,335 3,218 Less: accumulated depreciation and amortization (2,234 ) (1,893 ) Fixed assets, net $ 1,101 $ 1,325 Depreciation and amortization expense for the three and nine months ended September 30, 2023 was $ 111 341 128 381 10 46

Leases

Leases	9 Months Ended
	Sep. 30, 2023
Leases
Leases	Note 7 – Leases The Company leases offices in Fort Lauderdale, Florida and Israel which expire in November 2024 and December 2023 leases vehicles under operating leases that expire at various dates through 2025 The components of lease cost and supplemental balance sheet information for the Company’s lease portfolio were as follows: Schedule of Lease Cost and Supplemental Balance Sheet Information 2023 2022 2023 2022 Three Months ended September 30, Nine Months ended September 30, 2023 2022 2023 2022 Lease Cost Operating lease (income) cost, net of related party license fee $ (36 ) $ 16 $ (18 ) $ 78 Variable lease cost 103 30 167 90 Total lease cost $ 67 $ 46 $ 149 $ 168 As of September 30, As of December 31, 2023 2022 Assets Operating lease, right-of-use-asset $ 261 $ 428 Liabilities Current Operating lease liabilities $ 220 $ 245 Non-current Operating lease liabilities, net of current portion 34 178 Total lease liabilities $ 254 $ 423 Other information: Weighted average remaining lease term - operating leases 1.36 1.79 Weighted-average discount rate - operating leases 7.33 % 7.36 % The Company’s lease expense is included in general and administrative expenses which is net of related party license fee of $ 67 66 202 173

Convertible Note and Long-Term

Convertible Note and Long-Term Debt	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Convertible Note and Long-Term Debt	Note 8 – Convertible Note and Long-Term Debt On July 16, 2021 (the “Effective Date”), the Company entered into a loan facility (the “Kreos Loan Agreement”) with Kreos Capital VI (Expert Fund) LP (the “Lender”). Under the Kreos Loan Agreement, the Lender will provide the Company with access to term loans in an aggregate principal amount of up to $ 12,000 4,000 5,000 3,000 The Convertible Note and Tranche B were funded on the Effective Date. As of December 31, 2021, the Company drew down the full $ 3,000 The Convertible Note requires forty-eight monthly interest only payments at 7.75 420 7.75 In connection with the Kreos Loan Agreement, the Company also issued to the Lender a warrant (“Warrant”), dated July 16, 2021, to purchase up to 636 314.22 The Company treated Tranche A, Tranche B and Tranche C, and the Warrant as three separate freestanding financial instruments with the proceeds received in connection with the transaction allocated amongst the instruments based on relative fair value. The proceeds received in connection with the transaction allocated amongst the instruments based on relative fair value resulted in $ 165 845 165 540 274 140 845 For the nine months ended September 30, 2023, interest expense for the Loan was as follows: Schedule of Interest Expense for Loan Contractual interest expense $ 690 Amortization of debt issuance costs 184 Total interest expense $ 874 For the three months ended September 30, 2023, interest expense for the Loan was as follows: Contractual interest expense $ 220 Amortization of debt issuance costs 61 Total interest expense $ 281 Future principal payments under the Convertible Note as of September 30, 2023 are as follows: Schedule of Future Principal Payments of Convertible Note Years Ending December 31, Amount 2023 (remaining 3 months) $ - 2024 - 2025 4,000 Total future principal payments 4,000 Less unamortized debt issuance costs 64 Total balance $ 3,936 Future principal payments under the Long-term Debt as of September 30, 2023 are as follows: Years Ending December 31, Amount 2023 (remaining 3 months) $ 703 2024 2,983 2025 1,601 Total future principal payments 5,287 End of loan payments 140 Less unamortized debt issuance costs of current portion of long-term debt (132 ) Less unamortized debt issuance costs of non-current portion of long-term debt (44 ) Total balance $ 5,252 Less long-term debt, current $ 2,781 Long-term debt, net of current portion $ 2,470

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9 – Commitments and Contingencies The Company has entered into and expects to enter into from time to time in the future, license agreements, strategic alliance agreements, assignment agreements, research service agreements, and similar agreements related to the advancement of its research and development efforts. Significant agreements are described in detail in the Company’s 2022 Form 10-K. While specific amounts will differ from quarter to quarter, the Company believes its overall activities regarding these agreements are materially consistent with those described in the 2022 Form 10-K. In addition to the specific agreements described in the 2022 Form 10-K, the Company has entered into, and will in the future enter into, other research and service provider agreements for the advancement of its research and development efforts. The Company expects to pay additional amounts in future periods in connection with existing and future research and service provider agreements. Royalty Payment Rights on Royalty Payment Rights Certificates The Company issued certain (i) Royalty Payment Rights Certificates, as amended (“Royalty Payment Rights Certificates”) to the former holders of the Company’s shares of Series A Convertible Preferred Stock, par value $ 0.0001 On September 12, 2023 (the “Effective Date”), the Company, entered into an Amendment Agreement (the “Amendment Agreement”) with the holders of a majority of the Royalty Payment Rights Certificates to cancel the rights of all Certificate Holders to receive the Royalty Amounts in exchange for an aggregate of 88,221 8,821 97,042 The Company measured the difference between the fair value of the shares of common stock issued and the carrying value (at a final fair value) of the royalty obligation as a gain. As the holder of a majority of the Royalty Payment Rights Certificates is considered a related party, as noted in Note 10, the Company recorded the extinguishment of the royalty obligation based on the total fair value of shares issued as well as the gain on settlement within equity as additional paid in capital as a capital transaction. Schedule of Extinguishment of Royalty Obligation Extinguishment of Royalty Obligation Balance at December 31, 2022 $ 1,212 Change in estimated fair value of royalty obligation (103 ) Balance at September 12, 2023 1,109 Contingent royalty obligation 1,109 Less fair value of common stock exchanged for extinguishment of royalty obligation 711 Gain on extinguishment – recorded within additional paid-in-capital $ 398

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 10 – Related Party Transactions Shared Space Agreement In January 2020, the Company entered into a license agreement (the “Shared Space Agreement”) with Orchestra BioMed, Inc. (OBIO), a greater than 5 212 270 67 202 66 173 Extinguishment of Royalty Obligation As noted in Note 9, under the Amendment Agreement, the Company extinguished its royalty obligation in exchange for equity interests. OBIO held the majority of the Royalty Payment Rights Certificates, and as such approved the Amendment Agreement and the settlement exchange. OBIO received 46,768

Share-based compensation

Share-based compensation	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Share-based compensation	Note 11 – Share-based compensation The following table sets forth total non-cash share-based compensation for the issuance of common stock, options to purchase common stock, warrants to purchase common stock, and restricted stock unit awards by operating statement classification for the three and nine months ended September 30, 2023 and 2022: Schedule of Stock-based Compensation 2023 2022 2023 2022 Three Months ended September 30, Nine Months ended September 30, 2023 2022 2023 2022 Research and development $ 27 $ 96 $ 107 $ 292 Sales and marketing 5 60 6 184 General and administrative 61 285 251 947 Total $ 93 $ 441 $ 364 $ 1,423 As of September 30, 2023, unamortized share-based compensation for stock options was $ 468 1.20 Stock option and warrant activity A summary of the Company’s stock option and warrant activity is as follows: Schedule of Stock Option and Warrants Options Warrants Shares Underlying Options Weighted Average Exercise Price Shares Underlying Warrants Weighted Average Exercise Price Outstanding at December 31, 2022 26,567 $ 640.51 26,088 $ 759.26 Granted 45,712 $ 8.99 * 531,074 $ 6.03 Exercised - $ - (79,866 ) $ - Expired (6,311 ) $ 662.79 (3,888 ) $ 1,587.38 Forfeited (3,380 ) $ 202.16 - $ - Outstanding at September 30, 2023 62,588 $ 200.79 473,408 $ 9.16 Exercisable at September 30, 2023 15,551 $ 764.46 473,408 $ 9.16 * Includes 241,134 0.0001 As of September 30, 2023, there were 563 80.63 1,346 277.57 As of September 30, 2023, unamortized stock compensation for restricted stock units was $ 36 0.60 Issuance of Warrants to Purchase Common Stock In February 2020, the Company entered into a services agreement whereby it agreed to issue warrants to purchase 400 849.00 400 150 0 26 Private Placement Offering On May 17, 2023, the Company entered into a securities purchase agreement with an accredited investor pursuant to which it agreed to issue and sell in a private placement an aggregate of (i) 35,000 241,134 276,134 12.675 12.674 3.0 0.5 0.2 10.80 0.0001 The measurement of fair value of the Pre-Funded Warrants was determined utilizing a Black-Scholes model. The relative fair value of these Pre-Funded Warrants was estimated to be $ 1.7 The measurement of fair value of the Common Warrants was determined utilizing a Black-Scholes model. The relative fair value of these Common Stock Warrants was estimated to be $ 1.5 In addition, pursuant to the terms of the offering, the Company issued the placement agent, H.C. Wainwright & Co., LLC., warrants to purchase up to 13,806 shares of the Company’s common stock (the “Placement Agent Warrants”). The Placement Agent Warrants are exercisable for a period of five and one-half years from the issuance date, at an exercise price of $ 15.845 As of November 13, 2023, Pre-Funded Warrants for 241,134 Additionally, in connection with the Private Placement, the Company entered into a warrant amendment (the “Warrant Amendment”), dated May 17, 2023 with the holder named therein, pursuant to which the Company agreed to amend certain existing warrants to purchase up to an aggregate of 19,999 636.00 after the 1-to-20 reverse stock split 10.80 1.875 0.1 The Private Placement resulted in net proceeds of approximately $ 3.0 0.5 0.2

Restructuring

Restructuring	9 Months Ended
	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
Restructuring	Note 12 – Restructuring In January 2023, the Company commenced a strategic restructuring program aimed at capital preservation. In April 2023, the Company approved the implementation of additional cost cutting measures, including an executive reorganization and other cuts in clinical expenses, in connection with its ongoing efforts to reduce operating expenses. In addition, the non-management members of the Board agreed to defer their Board fees until a future date 0 1,517 94 The components of the restructuring charges included in the condensed consolidated statements of comprehensive loss for the nine months ended September 30, 2023 were as follows: Schedule of Restructuring Liabilities included in Accounts Payable and Accrued Expenses Employee Restructuring expenses- Sales and Marketing $ 566 Restructuring expenses- Research and Development 449 Restructuring expenses- General and Administrative 502 Total restructuring charges $ 1,517

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 13 – Subsequent Events On November 2, 2023, the Company effected the 2023 Reverse Stock Split and as part of the adjustment to reflect the 2023 Reverse Stock Split, the Company will be paying a de minimus cash payout to stockholders who would otherwise be entitled to a fractional share of common stock. See Note 3 for further discussion.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Reverse Stock Split	Reverse Stock Split On November 2, 2023, the Company effected a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share, at a ratio of 1-for-15 (the “2023 Reverse Stock Split”) No fractional shares were issued in connection with the 2023 Reverse Stock Split. Stockholders who would otherwise be entitled to a fractional share of common stock instead receive a proportional cash payment. All of the Company’s historical share and per share information related to issued and outstanding common stock and outstanding options and warrants exercisable for common stock in these condensed consolidated financial statements have been adjusted, on a retroactive basis, to reflect the 2023 Reverse Stock Split.
Basis of presentation and principles of consolidation	Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and include the accounts of the Company and its wholly owned subsidiaries, Motus Ltd., an Israel corporation, which has operations in Tirat Carmel, Israel, and Motus Inc., a Delaware corporation, which has operations in the U.S. All inter-company accounts and transactions have been eliminated in consolidation.
Use of estimates	Use of estimates The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Basic and diluted net loss per share	Basic and diluted net loss per share Basic net loss per share is calculated by dividing the net loss attributable to common shareholders by the weighted average number of common shares outstanding during the applicable period. Diluted net loss per share is calculated by dividing the net loss attributable to common shareholders by the weighted average number of common shares outstanding for the applicable period, including any potentially dilutive securities such as stock options, unvested restricted stock, warrants, and other convertible instruments unless the result of inclusion would be antidilutive. The dilutive effect of restricted stock units subject to vesting and other share-based payment awards is calculated using the “treasury stock method,” which assumes that the “proceeds” from the exercise of these instruments are used to purchase common shares at the average market price for the period. The dilutive effect of convertible securities is calculated using the “if-converted method.” Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted calculation for the entire period being presented. Given the nominal exercise price of the Company’s issuance of Pre-Funded Warrants, such Pre-Funded Warrants are included in in the calculation of basic and diluted net loss per share as the exercise price per warrant is deemed nonsubstantive when compared to the fair value of the underlying common shares. The 161,266 The Company’s Convertible Note, on an as converted basis into common stock of 9,523 Schedule of Anti-dilutive Effect 2023 2022 2023 2022 Three Months Ended Nine Months Ended 2023 2022 2023 2022 Outstanding options 62,589 26,642 62,589 26,642 Unvested restricted stock units 1,079 1,630 1,079 1,630 Warrants 312,143 26,238 312,143 26,238 Total 375,811 54,510 375,811 54,510
Income taxes	Income taxes The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of September 30, 2023 and December 31, 2022, the Company had a full valuation allowance against its deferred tax assets. For the three and nine months ended September 30, 2023 and 2022, the Company recorded zero income tax expense. No tax benefit has been recorded in relation to the pre-tax loss for the three and nine months ended September 30, 2023 and 2022, due to a full valuation allowance to offset any deferred tax asset related to net operating loss carry forwards attributable to the losses.
Accounting Pronouncements- Adopted	Accounting Pronouncements- Adopted In September 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses” to improve information on credit losses for financial assets and net investment in leases that are not accounted for at fair value through net income. ASU 2016-13 replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses. In April 2019 and May 2019, the FASB issued ASU No. 2019-04, “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments” and ASU No. 2019-05, “Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief” which provided additional implementation guidance on the previously issued ASU. In November 2019, the FASB issued ASU 2019-10, “Financial Instruments - Credit Loss (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842),” which defers the effective date for public filers that are considered smaller reporting companies as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company adopted this ASU on January 1, 2023. The adoption of this ASU did not result in a material impact to the consolidated financial statements and disclosures.
Accounting Pronouncements- Not Yet Adopted	Accounting Pronouncements- Not Yet Adopted In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Schedule of Anti-dilutive Effect	Schedule of Anti-dilutive Effect 2023 2022 2023 2022 Three Months Ended Nine Months Ended 2023 2022 2023 2022 Outstanding options 62,589 26,642 62,589 26,642 Unvested restricted stock units 1,079 1,630 1,079 1,630 Warrants 312,143 26,238 312,143 26,238 Total 375,811 54,510 375,811 54,510

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Financial Assets and Liabilities	Liabilities measured and recorded at fair value on a recurring basis consisted of the following at September 30, 2023 and December 31, 2022: Schedule of Fair Value of Financial Assets and Liabilities September 30, 2023 Level 1 Level 2 Level 3 Fair Value Liabilities Contingent royalty obligation $ - $ - $ - $ - December 31, 2022 Level 1 Level 2 Level 3 Fair Value Liabilities Contingent royalty obligation $ - $ - $ 1,212 $ 1,212

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory at September 30, 2023 and December 31, 2022 consisted of the following: Schedule of Inventory September 30, 2023 December 31, 2022 Raw materials $ 554 $ 697 Work-in-process 177 155 Finished goods 672 548 Inventory reserve (622 ) (401 ) Inventory, net $ 781 $ 999 Inventory, current $ 407 $ 488 Inventory, non-current $ 374 $ 511

Fixed assets, net (Tables)

Fixed assets, net (Tables)	9 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets Net	Fixed assets, summarized by major category, consist of the following for the years ended: Schedule of Fixed Assets Net September 30, 2023 December 31, 2022 Office equipment $ 171 $ 171 Computers and software 321 321 Machinery 1,154 1,049 Lab and medical equipment 1,489 1,477 Leasehold improvements 200 200 Total 3,335 3,218 Less: accumulated depreciation and amortization (2,234 ) (1,893 ) Fixed assets, net $ 1,101 $ 1,325

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2023
Leases
Schedule of Lease Cost and Supplemental Balance Sheet Information	The components of lease cost and supplemental balance sheet information for the Company’s lease portfolio were as follows: Schedule of Lease Cost and Supplemental Balance Sheet Information 2023 2022 2023 2022 Three Months ended September 30, Nine Months ended September 30, 2023 2022 2023 2022 Lease Cost Operating lease (income) cost, net of related party license fee $ (36 ) $ 16 $ (18 ) $ 78 Variable lease cost 103 30 167 90 Total lease cost $ 67 $ 46 $ 149 $ 168 As of September 30, As of December 31, 2023 2022 Assets Operating lease, right-of-use-asset $ 261 $ 428 Liabilities Current Operating lease liabilities $ 220 $ 245 Non-current Operating lease liabilities, net of current portion 34 178 Total lease liabilities $ 254 $ 423 Other information: Weighted average remaining lease term - operating leases 1.36 1.79 Weighted-average discount rate - operating leases 7.33 % 7.36 %

Convertible Note and Long-Ter_2

Convertible Note and Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Schedule of Interest Expense for Loan	For the nine months ended September 30, 2023, interest expense for the Loan was as follows: Schedule of Interest Expense for Loan Contractual interest expense $ 690 Amortization of debt issuance costs 184 Total interest expense $ 874 For the three months ended September 30, 2023, interest expense for the Loan was as follows: Contractual interest expense $ 220 Amortization of debt issuance costs 61 Total interest expense $ 281
Schedule of Future Principal Payments of Convertible Note	Future principal payments under the Convertible Note as of September 30, 2023 are as follows: Schedule of Future Principal Payments of Convertible Note Years Ending December 31, Amount 2023 (remaining 3 months) $ - 2024 - 2025 4,000 Total future principal payments 4,000 Less unamortized debt issuance costs 64 Total balance $ 3,936 Future principal payments under the Long-term Debt as of September 30, 2023 are as follows: Years Ending December 31, Amount 2023 (remaining 3 months) $ 703 2024 2,983 2025 1,601 Total future principal payments 5,287 End of loan payments 140 Less unamortized debt issuance costs of current portion of long-term debt (132 ) Less unamortized debt issuance costs of non-current portion of long-term debt (44 ) Total balance $ 5,252 Less long-term debt, current $ 2,781 Long-term debt, net of current portion $ 2,470

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of Extinguishment of Royalty Obligation	Schedule of Extinguishment of Royalty Obligation Extinguishment of Royalty Obligation Balance at December 31, 2022 $ 1,212 Change in estimated fair value of royalty obligation (103 ) Balance at September 12, 2023 1,109 Contingent royalty obligation 1,109 Less fair value of common stock exchanged for extinguishment of royalty obligation 711 Gain on extinguishment – recorded within additional paid-in-capital $ 398

Share-based compensation (Table

Share-based compensation (Tables)	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-based Compensation	The following table sets forth total non-cash share-based compensation for the issuance of common stock, options to purchase common stock, warrants to purchase common stock, and restricted stock unit awards by operating statement classification for the three and nine months ended September 30, 2023 and 2022: Schedule of Stock-based Compensation 2023 2022 2023 2022 Three Months ended September 30, Nine Months ended September 30, 2023 2022 2023 2022 Research and development $ 27 $ 96 $ 107 $ 292 Sales and marketing 5 60 6 184 General and administrative 61 285 251 947 Total $ 93 $ 441 $ 364 $ 1,423
Schedule of Stock Option and Warrants	A summary of the Company’s stock option and warrant activity is as follows: Schedule of Stock Option and Warrants Options Warrants Shares Underlying Options Weighted Average Exercise Price Shares Underlying Warrants Weighted Average Exercise Price Outstanding at December 31, 2022 26,567 $ 640.51 26,088 $ 759.26 Granted 45,712 $ 8.99 * 531,074 $ 6.03 Exercised - $ - (79,866 ) $ - Expired (6,311 ) $ 662.79 (3,888 ) $ 1,587.38 Forfeited (3,380 ) $ 202.16 - $ - Outstanding at September 30, 2023 62,588 $ 200.79 473,408 $ 9.16 Exercisable at September 30, 2023 15,551 $ 764.46 473,408 $ 9.16 * Includes 241,134 0.0001

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Liabilities included in Accounts Payable and Accrued Expenses	The components of the restructuring charges included in the condensed consolidated statements of comprehensive loss for the nine months ended September 30, 2023 were as follows: Schedule of Restructuring Liabilities included in Accounts Payable and Accrued Expenses Employee Restructuring expenses- Sales and Marketing $ 566 Restructuring expenses- Research and Development 449 Restructuring expenses- General and Administrative 502 Total restructuring charges $ 1,517

Basis of Presentation and Goi_2

Basis of Presentation and Going Concern Uncertainty (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended	3 Months Ended						9 Months Ended
	Sep. 12, 2023	May 17, 2023	Mar. 31, 2021	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net loss				$ 2,679	$ 2,997	$ 4,386	$ 4,964	$ 5,140	$ 4,811	$ 10,062	$ 14,915
Net cash used in operating activities										9,300
Cash and cash equivalents				5,724						5,724		$ 14,042
Accumulated deficit				151,413						151,413		$ 141,351
Proceeds from issuance of common stock										$ 121	$ 4,544
Shares of common stock issued		35,000
Prefunded Warrant [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants to purchase shares		241,134
Share price		$ 12.6735
Net proceeds		$ 3,000
Proceeds from inclusive of issuance costs		500
Proceeds from exclusive of warrant issuance costs		$ 200
Common Warrants [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants to purchase shares		276,134
Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net loss
Shares of common stock issued	97,042					7,942	17,208	541	19,917
Share price		$ 12.675
Equity Distribution Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of common stock sold, shares										7,942
Proceeds from issuance of common stock										$ 102
Proceeds from net of issuance costs										$ 19
Equity Distribution Agreement [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate of offering cost			$ 25,000

Schedule of Anti-dilutive Effec

Schedule of Anti-dilutive Effect (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	375,811	54,510	375,811	54,510
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	62,589	26,642	62,589	26,642
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,079	1,630	1,079	1,630
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	312,143	26,238	312,143	26,238

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - shares			9 Months Ended
	Nov. 02, 2023	May 17, 2023	Sep. 30, 2023	Dec. 31, 2022
Reverse stock split	On November 2, 2023, the Company effected a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share, at a ratio of 1-for-15 (the “2023 Reverse Stock Split”)
Common stock, shares issued		35,000	530,449	310,494
Prefunded Warrant [Member]
Common stock, shares issued			161,266
Common Stock [Member]
Reverse stock split		after the 1-to-20 reverse stock split
Common stock, shares issued		276,134
Converted basis, shares			9,523

Schedule of Fair Value of Finan

Schedule of Fair Value of Financial Assets and Liabilities (Details) - Contingent Royalty Obligation [Member] - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent royalty obligation
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent royalty obligation
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent royalty obligation
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent royalty obligation		$ 1,212

Fair Value Measurements (Detail

Fair Value Measurements (Details Narrative)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Rate of royalty payment	3%	3%
Measurement Input, Discount Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Discount rate	28.50%	23%

Schedule of Inventory (Details)

Schedule of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 554	$ 697
Work-in-process	177	155
Finished goods	672	548
Inventory reserve	(622)	(401)
Inventory, net	781	999
Inventory, current	407	488
Inventory, non-current	$ 374	$ 511

Inventory (Details Narrative)

Inventory (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Inventory Disclosure [Abstract]
Impairment of inventory	$ 26	$ 0	$ 221	$ 159

Schedule of Fixed Assets Net (D

Schedule of Fixed Assets Net (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Total	$ 3,335	$ 3,218
Less: accumulated depreciation and amortization	(2,234)	(1,893)
Fixed assets, net	1,101	1,325
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	171	171
Computers And Software [Member]
Property, Plant and Equipment [Line Items]
Total	321	321
Machinery [Member]
Property, Plant and Equipment [Line Items]
Total	1,154	1,049
Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	1,489	1,477
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total	$ 200	$ 200

Fixed assets, net (Details Narr

Fixed assets, net (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 111	$ 128	$ 341	$ 381
Impairment of fixed assets		$ 10		$ 46

Schedule of Lease Cost and Supp

Schedule of Lease Cost and Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Leases
Operating lease (income) cost, net of related party license fee	$ (36)	$ 16	$ (18)	$ 78
Variable lease cost	103	30	167	90
Total lease cost	67	$ 46	149	$ 168
Operating lease, right-of-use- asset	261		261		$ 428
Operating lease liabilities, current	220		220		245
Operating lease liabilities, net of current portion	34		34		178
Total lease liabilities	$ 254		$ 254		$ 423
Weighted average remaining lease term - operating leases	1 year 4 months 9 days		1 year 4 months 9 days		1 year 9 months 14 days
Weighted-average discount rate - operating leases	7.33%		7.33%		7.36%

Leases (Details Narrative)

Leases (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Property, Plant and Equipment [Line Items]
License fees	$ 67	$ 66	$ 202	$ 173
Office [Member] | Florida and Israel [Member]
Property, Plant and Equipment [Line Items]
Operating lease, description			leases offices in Fort Lauderdale, Florida and Israel which expire in November 2024 and December 2023
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Operating lease, description			leases vehicles under operating leases that expire at various dates through 2025

Schedule of Interest Expense fo

Schedule of Interest Expense for Loan (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023
Debt Disclosure [Abstract]
Contractual interest expense	$ 220	$ 690
Amortization of debt issuance costs	61	184
Total interest expense	$ 281	$ 874

Schedule of Future Principal Pa

Schedule of Future Principal Payments of Convertible Note (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Short-Term Debt [Line Items]
Less long-term debt, current	$ 2,781	$ 2,532
Long-term debt, net of current portion	2,470	$ 4,589
Convertible Note [Member]
Short-Term Debt [Line Items]
2023 (remaining 3 months)
2024
2025	4,000
Total future principal payments	4,000
Less unamortized debt issuance costs	64
Total balance	3,936
Long-Term Debt [Member]
Short-Term Debt [Line Items]
2023 (remaining 3 months)	703
2024	2,983
2025	1,601
Total future principal payments	5,287
Total balance	5,252
End of loan payments	140
Less unamortized debt issuance costs of current portion of long-term debt	(132)
Less unamortized debt issuance costs of non-current portion of long-term debt	(44)
Less long-term debt, current	2,781
Long-term debt, net of current portion	$ 2,470

Convertible Note and Long-Ter_3

Convertible Note and Long-Term Debt (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended	12 Months Ended
	Jul. 16, 2021	Sep. 30, 2023	Dec. 31, 2021	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Exercise price		$ 0.0001
Long term debt		$ 2,781		$ 2,532
Tranche C [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument, periodic payment, principal	$ 3,000		$ 3,000
Kreos Loan Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument, periodic payment, principal	$ 12,000
Debt instrument, interest rate		7.75%
Debt instrument, convertible, conversion price		$ 420
Warrant issued to purchase common shares	636
Exercise price	$ 314.22
Fair value of warrant		$ 165
Advance payment		845
Payments of debt issuance costs		540
Advance payments for debt discount		274
Long term debt		140
Kreos Loan Agreement [Member] | Warrant [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Advance payment		$ 165
Kreos Loan Agreement [Member] | Tranche A [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument, periodic payment, principal	$ 4,000
Kreos Loan Agreement [Member] | Tranche B [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument, periodic payment, principal	$ 5,000

Schedule of Extinguishment of R

Schedule of Extinguishment of Royalty Obligation (Details) - USD ($) $ in Thousands	8 Months Ended	9 Months Ended
	Sep. 12, 2023	Sep. 30, 2023	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Balance at December 31, 2022	$ 1,212	$ 1,212
Change in estimated fair value of royalty obligation	(103)	(103)	$ 29
Contingent royalty obligation	1,109
Less fair value of common stock exchanged for extinguishment of royalty obligation	711
Gain on extinguishment – recorded within additional paid-in-capital	$ 398

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) - $ / shares			3 Months Ended
	Sep. 12, 2023	May 17, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023
Exchange of shares	88,221
Exchange of shares, cancelled	8,821
Stock Issued During Period, Shares, New Issues		35,000
Common Stock [Member]
Stock Issued During Period, Shares, New Issues	97,042		7,942	17,208	541	19,917
Series A Convertible Preferred Stock [Member]
Preferred stock, par value							$ 0.0001

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Jan. 31, 2020
License fee	$ 67	$ 66	$ 202	$ 173
Orchestra Bio Med Inc [Member]
Settlement exchange of shares	46,768		46,768
Minimum [Member]
License fee			$ 212
Maximum [Member]
License fee			$ 270
Shared Space Agreements [Member] | Orchestra Bio Med Inc [Member]
Ownership percentage					5%

Schedule of Stock-based Compens

Schedule of Stock-based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 93	$ 441	$ 364	$ 1,423
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	27	96	107	292
Selling, General and Administrative Expenses [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	5	60	6	184
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 61	$ 285	$ 251	$ 947

Schedule of Stock Option and Wa

Schedule of Stock Option and Warrants (Details) - $ / shares			9 Months Ended
		Sep. 12, 2023	Sep. 30, 2023
Offsetting Assets [Line Items]
Shares underlying options, forfeited		(8,821)
Warrant [Member]
Offsetting Assets [Line Items]
Shares Underlying Warrants, Outstanding beginning			26,088
Weighted Average Exercise Price, Outstanding beginning			$ 759.26
Shares Underlying Warrants, granted	[1]		531,074
[custom:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageGrantedPrice]			$ 6.03
Shares Underlying Warrants, exercised			(79,866)
Weighted Average Exercise Price, granted
Shares Underlying Warrants, expired			(3,888)
Weighted Average Exercise Price, expired			$ 1,587.38
Shares Underlying Warrants, forfeited
Weighted Average Exercise Price, forfeited
Shares Underlying Warrants, outstanding ending			473,408
Weighted Average Exercise Price, outstanding ending			$ 9.16
Shares Underlying Warrants, exercisable			473,408
Weighted Average Exercise Price, exercisable			$ 9.16
Equity Option [Member]
Offsetting Assets [Line Items]
Shares underlying options, outstanding beginning			26,567
Weighted average exercise price, outstanding beginning			$ 640.51
Shares underlying options, granted			45,712
Weighted average exercise price, granted			$ 8.99
Shares underlying options, exercised
Weighted average exercise price, Exercises
Shares underlying options, expired			(6,311)
Weighted average exercise price, expired			$ 662.79
Shares underlying options, forfeited			(3,380)
Weighted average exercise price, forfeited			$ 202.16
Shares underlying options, outstanding ending			62,588
Weighted average exercise price, outstanding ending			$ 200.79
Shares underlying options, exercisable			15,551
Weighted average exercise price, exercisable			$ 764.46
[1]Includes 241,134 0.0001

Schedule of Stock Option and _2

Schedule of Stock Option and Warrants (Details) (Parenthetical)	Sep. 30, 2023 $ / shares shares
Exercise price | $ / shares	$ 0.0001
Warrant [Member]
Warrant, shares | shares	241,134

Share-based compensation (Detai

Share-based compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands					9 Months Ended
	Nov. 13, 2023	Nov. 02, 2023	May 19, 2023	May 17, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Feb. 29, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price					$ 0.0001
Share based compensation					$ 0	$ 26
Common stock, shares issued				35,000	530,449		310,494
Reverse stock split		On November 2, 2023, the Company effected a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share, at a ratio of 1-for-15 (the “2023 Reverse Stock Split”)
Private Placement [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Net proceeds					$ 3,000
Proceeds from inclusive of issuance costs					500
Proceeds from exclusive of warrant issuance costs					$ 200
Share price				$ 1.875
Reduced exercise price				$ 10.80
Incremental fair value				$ 100
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants to purchase of common stock					241,134
Number of warrant purchase, shares				241,134
Share price				$ 10.80
Number of shares of stock exercised					79,866
Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price				$ 636
Common stock, shares issued				276,134
Shares Issued Price Per, Share				$ 12.675
Share price				$ 12.675
Class of warrant or right outstanding				19,999
Reverse stock split				after the 1-to-20 reverse stock split
Prefunded Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price				$ 0.0001
Common stock, shares issued					161,266
Number of warrant purchase, shares				241,134
Shares Issued Price Per, Share				$ 12.674
Net proceeds				$ 3,000
Proceeds from inclusive of issuance costs				500
Proceeds from exclusive of warrant issuance costs				$ 200
Share price				$ 12.6735
Fair value adjustment of warrants			$ 1,700
Common Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value adjustment of warrants					$ 1,500
Placement Agent Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price					$ 15.845
Prefunded Warrants [Member] | Subsequent Event [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares of stock exercised	241,134
Services Agreement [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price								$ 150
Services Agreement [Member] | Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants to purchase of common stock								400
Exercise price								$ 849
Services Agreement [Member] | Replacement Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants to purchase of common stock								400
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average recognition period					7 months 6 days
Number of shares nonvested stock unit awards					563		1,346
Weighted average grant date fair value					$ 80.63		$ 277.57
Unamortization stock compensation					$ 36
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock based compensation for stock options					$ 468
Weighted-average recognition period					1 year 2 months 12 days

Schedule of Restructuring Liabi

Schedule of Restructuring Liabilities included in Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	$ 94	$ 1,517
Selling and Marketing Expense [Member]
Restructuring Cost and Reserve [Line Items]
Total restructuring charges		566
Research and Development Expense [Member]
Restructuring Cost and Reserve [Line Items]
Total restructuring charges		449
General and Administrative Expense [Member]
Restructuring Cost and Reserve [Line Items]
Total restructuring charges		$ 502

Restructuring (Details Narrativ

Restructuring (Details Narrative) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended
	Jan. 31, 2023	Sep. 30, 2023	Sep. 30, 2023
Restructuring Cost and Reserve [Line Items]
Restructuring description	the Company commenced a strategic restructuring program aimed at capital preservation. In April 2023, the Company approved the implementation of additional cost cutting measures, including an executive reorganization and other cuts in clinical expenses, in connection with its ongoing efforts to reduce operating expenses. In addition, the non-management members of the Board agreed to defer their Board fees until a future date
Restructuring charges		$ 94	$ 1,517
Strategic Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 0	$ 1,517